GB2603379A - Avocatin B for the treatment of diseases and conditions - Google Patents
Avocatin B for the treatment of diseases and conditions Download PDFInfo
- Publication number
- GB2603379A GB2603379A GB2204662.7A GB202204662A GB2603379A GB 2603379 A GB2603379 A GB 2603379A GB 202204662 A GB202204662 A GB 202204662A GB 2603379 A GB2603379 A GB 2603379A
- Authority
- GB
- United Kingdom
- Prior art keywords
- subject
- avocatin
- metabolic disorder
- effective amount
- therapeutically effective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000010099 disease Diseases 0.000 title claims abstract 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract 6
- 238000000034 method Methods 0.000 claims abstract 21
- 208000030159 metabolic disease Diseases 0.000 claims abstract 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 9
- 239000008103 glucose Substances 0.000 claims 9
- 206010022489 Insulin Resistance Diseases 0.000 claims 8
- 208000008589 Obesity Diseases 0.000 claims 4
- 230000004190 glucose uptake Effects 0.000 claims 4
- 230000003914 insulin secretion Effects 0.000 claims 4
- 235000020824 obesity Nutrition 0.000 claims 4
- 230000003647 oxidation Effects 0.000 claims 4
- 238000007254 oxidation reaction Methods 0.000 claims 4
- 210000004923 pancreatic tissue Anatomy 0.000 claims 4
- 210000002027 skeletal muscle Anatomy 0.000 claims 4
- 210000001519 tissue Anatomy 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- 230000037213 diet Effects 0.000 claims 2
- 235000005911 diet Nutrition 0.000 claims 2
- 230000008482 dysregulation Effects 0.000 claims 2
- 230000000512 lipotoxic effect Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000003642 reactive oxygen metabolite Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A method of treating a disease or condition may be characterized by a metabolic disorder in a subject in need thereof, that can include administering to the subject a therapeutically effective amount of avocatin B.
Claims (37)
1. A method of treating a disease or condition characterized by a metabolic disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of avocatin B.
2. The method of claim 1, wherein the metabolic disorder is characterized by dysregulation of glucose-stimulated insulin secretion (GSIS) in the subject.
3. The method of claim 1, wherein the metabolic disorder is characterized by insulin resistance in the subject.
4. The method of claim 1, wherein the metabolic disorder is characterized by reduced insulin sensitivity in the subject.
5. The method according to any one of claims 1 to 4, wherein the disease or condition is diet-induced obesity.
6. The method of claim 1, wherein the metabolic disorder is characterized by obesity associated lipotoxicity in the subject and the method further comprises rescuing glucose-stimulated insulin secretion (GSIS) in the subject.,
7. The method of claim 1, further comprising increasing glucose utilization in the subject.
8. The method of claim 1, further comprising modulating reactive oxygen species in the subject.
9. The method of claim 1, further comprising increasing glucose uptake in pancreatic tissue in the subject.
10. The method of claim 1, further comprising increasing glucose uptake in skeletal muscle tissue in the subject.
11. The method of claim 1, further comprising increasing glucose oxidation in pancreatic tissue in the subject. .
12. The method of claim 1 , further comprising increasing glucose oxidation in skeletal muscle tissue in the subject. .
13. The method of claim 1, further comprising reversing insulin resistance in the subject. ..
14. The method of claim 1, further comprising increasing insulin sensitivity in the subject. .
15. The method according to any one of claims 1 to 14 wherein the therapeutically effective amount of avocatin B is administered in at least one daily dose.
16. The method according to claim 15, wherein the at least one daily dose comprises from about 25 mg to about 200 mg of avocatin B.
17. The method according to claim 15, wherein the at least one daily dose comprises about 50 mg of avocatin B.
18. Use of a therapeutically effective amount of avocatin B for treating a disease or condition characterized by a metabolic disorder in a subject in need thereof.
19. The use of claim 1, wherein the metabolic disorder is characterized by dysregulation of glucose- stimulated insulin secretion (GSIS) in the subject.
20. The use of claim 1, wherein the metabolic disorder is characterized by insulin resistance in the subject.
21. The use of claim 1, wherein the metabolic disorder is characterized by reduced insulin sensitivity in the subject.
22. The use according to any one of claims 1 to 4, wherein the disease or condition is diet-induced obesity.
23. The use of claim 1, wherein the metabolic disorder is characterized by obesity associated lipotoxicity in the subject and the method further comprises rescuing glucose-stimulated insulin secretion (GSIS) in the subject.,
24. The use of claim 1, further comprising increasing glucose utilization in the subject.
25. The use of claim 1, further comprising modulating reactive oxygen species in the subject.
26. The use of claim 1, further comprising increasing glucose uptake in pancreatic tissue in the subject.
27. The use of claim 1, further comprising increasing glucose uptake in skeletal muscle tissue in the subject.
28. The use of claim 1, further comprising increasing glucose oxidation in pancreatic tissue in the subject. .
29. The use of claim 1, further comprising increasing glucose oxidation in skeletal muscle tissue in the subject. .
30. The use of claim 1, further comprising reversing insulin resistance in the subject. ..
31. The use of claim 1, further comprising increasing insulin sensitivity in the subject. .
32. The use according to any one of claims 18 to 31, wherein the therapeutically effective amount of avocatin B is administered in at least one daily dose.
33. The use according to claim 32, wherein the at least one daily dose comprises from about 25 mg to about 200 mg of avocatin B.
34. The use according to claim 32, wherein the at least one daily dose comprises about 50 mg of avocatin B.
35. A pharmaceutical composition comprising: a therapeutically effective amount of avocatin B and a carrier.
36. The composition of claim 35, wherein the therapeutically effective amount comprises from about 25 mg to about 200 mg.
37. The composition of claim 35, wherein the therapeutically effective amount comprises about 50 mg.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962897069P | 2019-09-06 | 2019-09-06 | |
| US201962899402P | 2019-09-12 | 2019-09-12 | |
| PCT/CA2020/051220 WO2021046646A1 (en) | 2019-09-12 | 2020-09-10 | Avocatin b for the treatment of diseases and conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| GB202204662D0 GB202204662D0 (en) | 2022-05-18 |
| GB2603379A true GB2603379A (en) | 2022-08-03 |
| GB2603379B GB2603379B (en) | 2023-04-12 |
Family
ID=81586509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB2204662.7A Active GB2603379B (en) | 2019-09-06 | 2020-09-10 | Avocatin B for the treatment of diseases and conditions |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB2603379B (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2964010A1 (en) * | 2014-10-09 | 2016-04-14 | Paul Anthony Spagnuolo | Avocado-derived lipids for use in treating leukemia |
-
2020
- 2020-09-10 GB GB2204662.7A patent/GB2603379B/en active Active
Non-Patent Citations (3)
| Title |
|---|
| CARVAJAL-ZARRABAL, Octavio et al., "Avocado Oil Supplementation Modifies Cardiovascular Risk Profile Markers in a Rat Model of Sucrose-Induced Metabolic Changes", Disease Markers, (20140225), pages 1 - 8 * |
| TABE, Y et al. "Inhibition of FAO in AML cocultured with BM adipocytes: mechanisms of survival and chemosensitization to cytarabine", Scientific Reports (2018), 8:16837, (15-11-2018) * |
| UCHENNA, Uzukwu Emmanuel, Shori Amal Bakr, Baba Ahmad Salihin, "Inclusion of avocado (Persea american a) seeds in the diet to improve carbohydrate and lipid metabolism in rats", Rivista Argentina Endocrinologia Y Metabolismo, (20170812), vol. 54, no. 3, pages 140 - 148 * |
Also Published As
| Publication number | Publication date |
|---|---|
| GB2603379B (en) | 2023-04-12 |
| GB202204662D0 (en) | 2022-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010140682A (en) | METHOD FOR TREATING PATIENTS FROM INFECTION, PHARMACEUTICAL COMPOSITION (OPTIONS) AND MEDICINE | |
| MXPA02002681A (en) | Use of g(a)-linolenic acid metabolites in the manufacture of a medicament for the treatment or prevention of cancer. | |
| DE602005009176D1 (en) | TREATMENT OF T-CELL LYMPHOMIC BY 10-PROPARGYL-10-DEAZAAMINEOPTERIN | |
| IL194500A0 (en) | Peptide substance enhancing capillaries resistance, pharmaceutical composition on its base and method of its application | |
| GB2603379A (en) | Avocatin B for the treatment of diseases and conditions | |
| TW200616644A (en) | Medicine for prevention or treatment of diabetes | |
| CA3150837A1 (en) | Avocatin b for the treatment of diseases and conditions | |
| LT2006024A (en) | Tetrapeptide regulating blood glucose level in diabetes mellitus | |
| CA2516458A1 (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
| MX2023003258A (en) | TREATMENT OF NF-κB-MEDIATED DISEASE. | |
| RU2537031C2 (en) | Method of treating cystitis | |
| RU2483723C1 (en) | Method of treating endocrine ophthalmopathy | |
| BRPI0405520A (en) | new diclofenac-derived drugs containing donor heterocycles, inflammation composition and treatment method | |
| PH12015502465A1 (en) | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias | |
| CN101322717A (en) | Medicament composition for preventing and treating eye diseases | |
| CA2469702A1 (en) | Darifenacin for use in the treatment of urgency induced by overactive bladder | |
| Amit Gupta | REAL-WORLD CLINICAL EFFECTIVENESS AND TOLERABILITY OF HYDROXYCHLOROQUINE 400MG IN T2DM | |
| Heathfield et al. | Treatment of petit mal with ethosuximide: follow-up report | |
| AU2016390920A1 (en) | New use of isoquinoline derivatives for diabetic wound healing | |
| TW200608965A (en) | Medicine for prevention or treatment of diabetes | |
| MX2024008256A (en) | Methods of treating coronavirus disease and compounds for same. | |
| MX2024005374A (en) | Methods of treating sickle cell disease with voxelotor. | |
| RU2249447C2 (en) | Method for treating the cases of tunnel syndromes | |
| MX2022012519A (en) | Endoxifen for the treatment of bipolar i disorder. | |
| MX2021008353A (en) | Use of nitazoxanide in the treatment of patients with covid-19. |